817 related articles for article (PubMed ID: 19443175)
1. The role of secondary cytoreductive surgery for recurrent mucinous epithelial ovarian cancer (mEOC).
Cheng X; Jiang R; Li ZT; Tang J; Cai SM; Zhang ZY; Tian WJ; Zang RY
Eur J Surg Oncol; 2009 Oct; 35(10):1105-8. PubMed ID: 19443175
[TBL] [Abstract][Full Text] [Related]
2. Impact of secondary cytoreductive surgery on survival of patients with advanced epithelial ovarian cancer.
Zang RY; Zhang ZY; Li ZT; Cai SM; Tang MQ; Chen J; Liu Q
Eur J Surg Oncol; 2000 Dec; 26(8):798-804. PubMed ID: 11087649
[TBL] [Abstract][Full Text] [Related]
3. Role of salvage cytoreductive surgery in the treatment of patients with recurrent ovarian cancer after platinum-based chemotherapy.
Matsumoto A; Higuchi T; Yura S; Mandai M; Kariya M; Takakura K; Fujii S
J Obstet Gynaecol Res; 2006 Dec; 32(6):580-7. PubMed ID: 17100820
[TBL] [Abstract][Full Text] [Related]
4. [Clinical significance of secondary cytoreductive surgery for recurrent advanced ovarian cancer].
Zang R; Zhang Z; Cai S
Zhonghua Zhong Liu Za Zhi; 2002 Mar; 24(2):194-6. PubMed ID: 12015048
[TBL] [Abstract][Full Text] [Related]
5. Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma.
Tebes SJ; Sayer RA; Palmer JM; Tebes CC; Martino MA; Hoffman MS
Gynecol Oncol; 2007 Sep; 106(3):482-7. PubMed ID: 17590420
[TBL] [Abstract][Full Text] [Related]
6. [Factors affecting disease recurrence and the role of secondary therapies in the management for patients with recurrent ovarian carcinoma].
Zang R; Zhang Z; Cai S
Zhonghua Fu Chan Ke Za Zhi; 2002 Sep; 37(9):546-9. PubMed ID: 12411017
[TBL] [Abstract][Full Text] [Related]
7. Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
Pectasides D; Fountzilas G; Aravantinos G; Kalofonos HP; Efstathiou E; Salamalekis E; Farmakis D; Skarlos D; Briasoulis E; Economopoulos T; Dimopoulos MA
Gynecol Oncol; 2005 May; 97(2):436-41. PubMed ID: 15863142
[TBL] [Abstract][Full Text] [Related]
8. Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer.
Santillan A; Karam AK; Li AJ; Giuntoli R; Gardner GJ; Cass I; Karlan BY; Bristow RE
Gynecol Oncol; 2007 Mar; 104(3):686-90. PubMed ID: 17141302
[TBL] [Abstract][Full Text] [Related]
9. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma.
Chi DS; McCaughty K; Diaz JP; Huh J; Schwabenbauer S; Hummer AJ; Venkatraman ES; Aghajanian C; Sonoda Y; Abu-Rustum NR; Barakat RR
Cancer; 2006 May; 106(9):1933-9. PubMed ID: 16572412
[TBL] [Abstract][Full Text] [Related]
10. Recurrent micropapillary serous ovarian carcinoma.
Bristow RE; Gossett DR; Shook DR; Zahurak ML; Tomacruz RS; Armstrong DK; Montz FJ
Cancer; 2002 Aug; 95(4):791-800. PubMed ID: 12209723
[TBL] [Abstract][Full Text] [Related]
11. [Secondary debulking surgery and intraperitoneal chemotherapy in advanced or recurrent epithelial ovarian cancer].
Plaisant N; Quenet F; Fabbro M; Gourgou S; Gutowski M; Saint-Aubert B; Rouanet P
Gynecol Obstet Fertil; 2004 May; 32(5):391-7. PubMed ID: 15177208
[TBL] [Abstract][Full Text] [Related]
12. Cytoreductive surgery and modified heated intraoperative intraperitoneal chemotherapy (HIPEC) for advanced and recurrent ovarian cancer -- 12-year single center experience.
Pavlov MJ; Kovacevic PA; Ceranic MS; Stamenkovic AB; Ivanovic AM; Kecmanovic DM
Eur J Surg Oncol; 2009 Nov; 35(11):1186-91. PubMed ID: 19356887
[TBL] [Abstract][Full Text] [Related]
13. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY
Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096
[TBL] [Abstract][Full Text] [Related]
14. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome.
Salani R; Santillan A; Zahurak ML; Giuntoli RL; Gardner GJ; Armstrong DK; Bristow RE
Cancer; 2007 Feb; 109(4):685-91. PubMed ID: 17219441
[TBL] [Abstract][Full Text] [Related]
15. Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer.
Gadducci A; Iacconi P; Cosio S; Fanucchi A; Cristofani R; Riccardo Genazzani A
Gynecol Oncol; 2000 Dec; 79(3):344-9. PubMed ID: 11104603
[TBL] [Abstract][Full Text] [Related]
16. Cytoreductive surgery for stage IV epithelial ovarian cancer.
Zang RY; Zhang ZY; Cai SM; Li ZT; Chen J; Tang MQ; Liu Q
J Exp Clin Cancer Res; 1999 Dec; 18(4):449-54. PubMed ID: 10746968
[TBL] [Abstract][Full Text] [Related]
17. Secondary cytoreductive surgery in patients presenting with isolated nodal recurrence of epithelial ovarian cancer.
Fotiou S; Aliki T; Petros Z; Ioanna S; Konstantinos V; Vasiliki M; George C
Gynecol Oncol; 2009 Aug; 114(2):178-82. PubMed ID: 19450872
[TBL] [Abstract][Full Text] [Related]
18. Secondary cytoreductive surgery for localized intra-abdominal recurrences in epithelial ovarian cancer.
Munkarah A; Levenback C; Wolf JK; Bodurka-Bevers D; Tortolero-Luna G; Morris RT; Gershenson DM
Gynecol Oncol; 2001 May; 81(2):237-41. PubMed ID: 11330956
[TBL] [Abstract][Full Text] [Related]
19. [How to increase the optimal rate of secondary cytoreductive surgery in recurrent epithelial ovarian cancer].
Li YF; Li MD; Liu FY; Liu JH; Li JD
Ai Zheng; 2003 Nov; 22(11):1193-6. PubMed ID: 14613651
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors and role of salvage surgery in chemorefractory ovarian germ cell malignancies: a study in Chinese patients.
Li J; Yang W; Wu X
Gynecol Oncol; 2007 Jun; 105(3):769-75. PubMed ID: 17459461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]